Registry of gastric cancer treatment evaluation (<scp>REGATE</scp>): <scp>I</scp> baseline disease characteristics

Bang, Yung Jue; Yalçın, Şuayib; Roth, Arnaud; Hitier, Simon; Тер-Ованесов, М. Д.; Wu, Chew Wun; Zalcberg, John

doi:10.1111/ajco.12112

Cited by 20 publications

(40 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the majority of first-line regimens administered to patients in this study consisted of a platinum agent and fluoropyrimidine as per eligibility criteria, second-line therapies varied widely, and include regimens that consisted of various single-agent fluoropyrimidines, doublet and triplet regimens, and single-agent taxanes. In a large, international prospective study of gastric cancer treatment (REGATE I), the use of a taxane such as paclitaxel, docetaxel, or irinotecan was reportedly the suggested second-line treatment for gastric cancer in Asia, though fewer than 10% of patients in the present sample were prescribed a taxane [1]. Other recent studies have reported a survival advantage associated with treatment with a second-line taxane such as docetaxel, or with irinotecan for cancers refractory to fluoropyrimidine and platinum treatment when compared to BSC [13,14].…”

Section: Discussionmentioning

confidence: 87%

“…Gastric cancer is the fourth most common cancer worldwide and the second most common cause of cancer-related deaths [1,2]. The incidence of gastric cancer is highest in East Asian countries and in some parts of South America, while its occurrence is lower in North America and Africa [1,3].…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of gastric cancer is highest in East Asian countries and in some parts of South America, while its occurrence is lower in North America and Africa [1,3]. South Korea has the highest incidence rate of gastric cancer (age standardized, male vs. female: 64.2 and 26.7 per 100,000).…”

Section: Introductionmentioning

confidence: 99%

“…There is high unmet need in gastric cancer as there are few approved agents, and treatment practices vary widely among countries [1,2], particularly in the second-line treatment setting. There is also limited information available on gastric cancer patient characteristics, healthcare resource use and treatment patterns [1,2,4].…”

Section: Introductionmentioning

confidence: 99%

“…There is also limited information available on gastric cancer patient characteristics, healthcare resource use and treatment patterns [1,2,4]. Therefore, this study was conducted to understand treatment patterns, patient outcomes, and healthcare resource use in South Korean patients with metastatic and/or locally recurrent, unresectable gastric cancer (MGC), including cancer of the stomach and gastroesophageal junction with adenocarcinoma histology.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Carter¹,

Kaltenboeck²,

Ivanova³

et al. 2014

JCO

Self Cite

View full text Add to dashboard Cite

Original ArticlePurpose The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. Materials and MethodsThirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. KaplanMeier analysis was used to describe survival. ResultsOf 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumors were located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity index was 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients. ConclusionMost patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Carter¹,

Kaltenboeck²,

Ivanova³

et al. 2014

JCO

Self Cite

View full text Add to dashboard Cite

show abstract

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

Chau

Ott

et al. 2019

Gastric Cancer

View full text Add to dashboard Cite

Background There are few third-line or later (3L+) treatment options for advanced/metastatic (adv/met) gastric cancer/gastroesophageal junction cancers (GC/GEJC). 3L+ Nivolumab demonstrated encouraging results in Asian patients in the ATTRACTION-2 study compared with placebo (12-month survival, 26% vs 11%), and in Western patients in the single-arm CheckMate 032 study (12-month survival, 44%). This analysis aimed to establish comparator cohorts of US patients receiving routine care in real-world (RW) clinical practice. Methods A 2-step matching process generated RW cohorts from Flatiron Health’s oncology database (January 1, 2011–April 30, 2017), for comparison with each trial: (1) clinical trial eligibility criteria were applied; (2) patients were frequency-matched with trial arms for baseline variables significantly associated with survival. Median overall survival (OS) was calculated by Kaplan–Meier analysis from last treatment until death. Results Of 742 adv/met GC/GEJC patients with at least 2 prior lines of therapy, matching generated 90 US RW ATTRACTION-2-matched patients (median OS: 3.5 months) versus 163 ATTRACTION-2 placebo patients (median OS: 4.1 months), and 100 US RW CheckMate 032-matched patients (median OS: 2.9 months) versus 42 CheckMate 032 nivolumab-treated patients (median OS: 8.5 months). Baseline characteristics were generally similar between clinical trial arms and RW-matched cohorts. Conclusions We successfully developed RW cohorts for comparison with data from clinical trials, with comparable baseline characteristics. Survival in US patients receiving RW care was similar to that seen in Asian patients receiving placebo in ATTRACTION-2; survival with nivolumab in CheckMate 032 appeared favorable compared with US RW clinical practice.

show abstract

Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer

Magdy

Hussein

Ezzat

et al. 2018

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics

Abstract: These results provide a comprehensive database representative of gastric cancer disease characteristics and treatment patterns across the world.

Cited by 20 publications

References 6 publications

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer

Contact Info

Product

Resources

About